BRIEF-Cartesian Therapeutics Inc - Phase 3 Aurora Topline Data In Myasthenia Gravis Expected In 1Q27 BLA Filing Planned Mid-2027

Cartesian Therapeutics

Cartesian Therapeutics

RNAC

0.00

May 26 (Reuters) - Cartesian Therapeutics Inc RNAC.O:

  • CARTESIAN THERAPEUTICS SECURES UP TO $150 MILLION OF NON-DILUTIVE FINANCING FROM K2 HEALTHVENTURES AND EXPECTS TOPLINE DATA FROM THE PHASE 3 AURORA TRIAL IN FIRST QUARTER 2027

  • CARTESIAN THERAPEUTICS INC - PHASE 3 AURORA TOPLINE DATA IN MYASTHENIA GRAVIS EXPECTED IN 1Q27; BLA FILING PLANNED MID-2027

Source text: ID:nGNX6rTrQD

Further company coverage: RNAC.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.